Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).Sumanta K. Pal, Sun Young Rha, Daniel Yick Chin Heng et al.|Journal of Clinical Oncology|2021Cited by 11